Subsidy Information and Financing Scheme SDLSofosbuvir & Velpatasvir Tablet, Sofosbuvir 400 mg + Velpatasvir 100 mg
Drug Guidance for Subsidy 04/06/2024 Direct-acting antiviral agents for treating chronic hepatitis C The Ministry of Health’s Drug Advisory Committee has recommended: Sofosbuvir 400 mg/velpatasv... See all × 04/06/2024 Direct-acting antiviral agents for treating chronic hepatitis C The Ministry of Health’s Drug Advisory Committee has recommended: Sofosbuvir 400 mg/velpatasvir 100 mg tablets in line with its registered indications for treating chronic hepatitis C. Funding status RSofosbuvir 400 mg/velpatasvir 100 mg tablet is recommended for inclusion on the Standard Drug List (SDL) from 1 August 2024. NROf note, glecaprevir 100 mg/pibrentasvir 40 mg tablet will be delisted from the MOH List of Subsidised Drugs with effect from 1 February 2025. 01/10/2020 Direct-acting antiviral agents for treating genotype 1 chronic hepatitis C The Ministry of Health’s Drug Advisory Committee has recommended: Sofosbuvir 400 mg/velpatas... See all × 01/10/2020 Direct-acting antiviral agents for treating genotype 1 chronic hepatitis C The Ministry of Health’s Drug Advisory Committee has recommended: Sofosbuvir 400 mg/velpatasvir 100 mg tablet for treating genotype 1 chronic hepatitis C infection in treatment-naïve, or pegylated interferon plus ribavirin (PR)-experienced, or NS3/4A protease inhibitor (boceprevir, simeprevir, telaprevir)-experienced adults. Glecaprevir 100 mg/pibrentasvir 40 mg tablet for treating genotype 1 chronic hepatitis C infection in treatment-naïve, or pegylated interferon plus ribavirin (with or without sofosbuvir)-experienced, or sofosbuvir plus ribavirin-experienced adults. Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir should be used in line with the recommended treatment regimens listed in the Annex. Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir should be prescribed by a specialist physician (gastroenterologist, hepatologist, or infectious disease specialist) with experience in the treatment of hepatitis C. The supplier of sofosbuvir/velpatasvir will provide retreatment with sofosbuvir/velpatasvir/voxilaprevir to patients who fail to achieve a sustained virological response with sofosbuvir/velpatasvir through their No Cure No Pay program, at no additional cost. Subsidy status RSofosbuvir 400mg/velpatasvir 100 mg tablet and glecaprevir 100 mg/pibrentasvir 40 mg tablet are recommended for inclusion on the Medication Assistance Fund (MAF), for the abovementioned indications. NRMAF assistance does not apply to other direct-acting antivirals (asunaprevir, ombitasvir/paritaprevir/ritonavir+dasabuvir, sofosbuvir/ledipasvir, elbasvir/grazoprevir and daclatasvir). 01/10/2020 Direct-acting antiviral agents for treating genotype 2 to 6 chronic hepatitis C The Ministry of Health’s Drug Advisory Committee has recommended: Sofosbuvir 400 mg/velpatas... See all × 01/10/2020 Direct-acting antiviral agents for treating genotype 2 to 6 chronic hepatitis C The Ministry of Health’s Drug Advisory Committee has recommended: Sofosbuvir 400 mg/velpatasvir 100 mg tablet for treating genotype 2, 3, 4, 5, or 6 chronic hepatitis C infection in treatment-naïve, or pegylated interferon plus ribavirin (PR)-experienced or NS3/4A protease inhibitor (boceprevir, simeprevir, telaprevir)-experienced adults; and Glecaprevir 100 mg/pibrentasvir 40 mg tablet for treating genotype 2, 3, 4, 5, or 6 chronic hepatitis C infection in treatment-naïve, or pegylated interferon plus ribavirin (with or without sofosbuvir)-experienced, or sofosbuvir plus ribavirin-experienced adults. Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir should be used in line with the recommended treatment regimens listed in the Annex. Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir should be prescribed by a specialist physician (gastroenterologist, hepatologist, or infectious disease specialist) with experience in treating hepatitis C. The supplier of sofosbuvir/velpatasvir will provide retreatment with sofosbuvir/velpatasvir/voxilaprevir to patients who fail to achieve a sustained virological response with sofosbuvir/velpatasvir through their No Cure No Pay program, at no additional cost. Subsidy status RSofosbuvir 400 mg/velpatasvir 100 mg tablet and glecaprevir 100 mg/pibrentasvir 40 mg tablet are recommended for inclusion on the Medication Assistance Fund (MAF), for the abovementioned indications. NRMAF assistance does not apply to other direct-acting antivirals (sofosbuvir, sofosbuvir/velpatasvir/voxilaprevir, sofosbuvir+daclatasvir, sofosbuvir/ledipasvir and elbasvir/grazoprevir).
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet, Sofosbuvir 400 mg + Velpatasvir 100 mg Alexandra Hospital Changi General Hospital Khoo Teck Puat Hospital Ng Teng Fong General Hospital National University Hospital Sengkang General Hospital Singapore General Hospital Tan Tock Seng Hospital Woodlands Health Campus